Ads
related to: preformation concepts in modern pharmaceutics pdf book free pk
Search results
Results From The WOW.Com Content Network
The first pharmacokinetic model described in the scientific literature [2] was in fact a PBPK model. It led, however, to computations intractable at that time. The focus shifted then to simpler models, [3] for which analytical solutions could be obtained (such solutions were sums of exponential terms, which led to further simplifications.)
PK/PD relationships can be described by simple equations such as linear model, Emax model or sigmoid Emax model. [5] However, if a delay is observed between the drug administration and the drug effect, a temporal dissociation needs to be taken into account and more complex models exist: [ 6 ] [ 7 ]
A homonculus inside a sperm cell, as drawn by Nicolaas Hartsoeker in 1695 Jan Swammerdam, Miraculum naturae sive uteri muliebris fabrica, 1729. In the history of biology, preformationism (or preformism) is a formerly popular theory that organisms develop from miniature versions of themselves.
Pharmacokinetics (from Ancient Greek pharmakon "drug" and kinetikos "moving, putting in motion"; see chemical kinetics), sometimes abbreviated as PK, is a branch of pharmacology dedicated to describing how the body affects a specific substance after administration. [1]
Pharmacodynamics is sometimes abbreviated as PD and pharmacokinetics as PK, especially in combined reference (for example, when speaking of PK/PD models). Pharmacodynamics places particular emphasis on dose–response relationships, that is, the relationships between drug concentration and effect. [1]
Pharmaceutical formulation, in pharmaceutics, is the process in which different chemical substances, including the active drug, are combined to produce a final medicinal product. The word formulation is often used in a way that includes dosage form .
In the field of pharmacokinetics, the area under the curve (AUC) is the definite integral of the concentration of a drug in blood plasma as a function of time (this can be done using liquid chromatography–mass spectrometry [1]).
The phrase "drug design" is similar to ligand design (i.e., design of a molecule that will bind tightly to its target). [6] Although design techniques for prediction of binding affinity are reasonably successful, there are many other properties, such as bioavailability, metabolic half-life, and side effects, that first must be optimized before a ligand can become a safe and effictive drug.